Canaccord Genuity Maintains Buy on Exact Sciences, Raises Price Target to $115
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Exact Sciences (NASDAQ:EXAS) and raises the price target from $92 to $115.
June 23, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on Exact Sciences and raises the price target from $92 to $115.
The raised price target by Canaccord Genuity analyst Kyle Mikson indicates a positive outlook for Exact Sciences. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100